Financing ·
Northwest Biotherapeutics borrows $5.5M from Streeterville Capital at 8% interest
NWBONorthwest Biotherapeutics Inc
On October 26, 2026, Northwest Biotherapeutics entered into a Commercial Loan Agreement with Streeterville Capital for $5,505,000. The loan carries an 8% annual interest rate and includes a 10% original issue discount. Repayment begins on June 26, 2027, with 14 equal monthly installments following an eight-month deferral period. Proceeds are designated for ongoing business operations. Northwest Biotherapeutics operates in the biotechnology industry, focusing on cancer immunotherapy.